TY - JOUR
T1 - Serum thrombopoietin (c-Mpl ligand) levels in patients with liver cirrhosis
AU - Shimodaira, Shigetaka
AU - Ishida, Fumihiro
AU - Ichikawa, Naoaki
AU - Tahara, Tomoyuki
AU - Kato, Takashi
AU - Kodaira, Hiroshi
AU - Ito, Toshiro
AU - Tanaka, Eiji
AU - Sodeyama, Takeshi
AU - Kiyosawa, Kendo
AU - Kitano, Kiyoshi
PY - 1996/10
Y1 - 1996/10
N2 - To clarify the role of c-Mpl ligand (thrombopoietin: TPO) in liver cirrhosis (LC), we examined serum TPO levels (sTPO) in patients with LC (N = 44), chronic hepatitis (CH; N = 13) and healthy controls (N = 41) by an enzyme-linked immunosorbent assay. Although platelet counts of all LC patients (89 ± 59 X 109/l; mean ± SD) were lower than those of controls and CH patients, sTPO levels in LC patients (1.23 ± 0.51 fmol/ml) were the same as those in controls (1.22 ± 0.37) and CH patients (1.18 ± 0.36). Platelet counts were significantly higher in splenectomized patients than in unsplenectomized patients, but the sTPO level did not differ between these two groups. In LC patients, the sTPO level was not correlated with the platelet count, but was correlated with prothrombin time, activated partial thromboplastin time, and total bilirubin, indicating that production of TPO in the liver decreases slightly with the development of liver dysfunction. Our findings suggest that production of TPO is maintained in LC patients and their thrombocytopenia is not due to a defect in platelet production.
AB - To clarify the role of c-Mpl ligand (thrombopoietin: TPO) in liver cirrhosis (LC), we examined serum TPO levels (sTPO) in patients with LC (N = 44), chronic hepatitis (CH; N = 13) and healthy controls (N = 41) by an enzyme-linked immunosorbent assay. Although platelet counts of all LC patients (89 ± 59 X 109/l; mean ± SD) were lower than those of controls and CH patients, sTPO levels in LC patients (1.23 ± 0.51 fmol/ml) were the same as those in controls (1.22 ± 0.37) and CH patients (1.18 ± 0.36). Platelet counts were significantly higher in splenectomized patients than in unsplenectomized patients, but the sTPO level did not differ between these two groups. In LC patients, the sTPO level was not correlated with the platelet count, but was correlated with prothrombin time, activated partial thromboplastin time, and total bilirubin, indicating that production of TPO in the liver decreases slightly with the development of liver dysfunction. Our findings suggest that production of TPO is maintained in LC patients and their thrombocytopenia is not due to a defect in platelet production.
UR - http://www.scopus.com/inward/record.url?scp=10344229413&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=10344229413&partnerID=8YFLogxK
U2 - 10.1055/s-0038-1650620
DO - 10.1055/s-0038-1650620
M3 - Article
C2 - 8902994
AN - SCOPUS:10344229413
SN - 0340-6245
VL - 76
SP - 545
EP - 548
JO - Thrombosis and Haemostasis
JF - Thrombosis and Haemostasis
IS - 4
ER -
